FDA Approves ESKATA for Seborrheic Keratoses

With ESKATA, healthcare providers and patients now have a topical treatment option that can clear raised SKs with a low risk of scarring.

[Image: Courtesy of Eskata][Image: Courtesy of Eskata]Aclaris Therapeutics have announced the FDA approval of ESKATA (hydrogen peroxide) topical solution, 40% (w/w) for the treatment of seborrheic keratoses (SKs), common skin growths affecting more than 83 million American adults. This noninvasive treatment option can clear raised SKs with a low risk of scarring.

 

RELATED: Spa Pros Share Their Favorite Antiaging Treatments

 

Important Safety Information

ESKATA (hydrogen peroxide) topical solution, 40% (w/w) is for use as an in-office treatment. The solution is applied by your healthcare provider and is not for use at home. Keep away from eyes.

Skin reactions occurred in and around the treatment area after application of the solution. Some were severe, including breakdown of the outer layer of the skin (erosion), ulcers, blisters and scarring.

The most common side effects of the product include itching, stinging, crusting, swelling, redness and scaling.

Tell your healthcare provider about any side effects that bother you or do not go away. Tell your healthcare provider right away if solution gets into your eyes, mouth or nose during application.

 

More in Home